This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human R-Spondin 1 / RSPO1 (21-146) Protein, His Tag
catalog :
RS6-H4220
quantity :
50 ug, 1 mg
price :
350 USD, 2360 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
RS6-H4220
product name :
Human R-Spondin 1 / RSPO1 (21-146) Protein, His Tag
quantity :
50 ug, 1 mg
price :
350 USD, 2360 USD
quantity & price :
$350/50ug,$2360/1mg (250ug × 4)
target :
R-Spondin 1
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human R-Spondin 1 (21-146), His Tag (RS6-H4220) is expressed from human 293 cells (HEK293). It contains AA Ser 21 - Ala 146 (Accession # AAI14967).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human R-Spondin 1 (21-146), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
R-spondin-1 is also known as Roof plate-specific Spondin 1 (RSPO1) and cysteinerich and single thrombospondin domain containing protein 3 (Cristin 3), which is a secreted protein which belongs to the R-Spondin family and encodes a secreted activator protein with two cystein-rich, furin-like domains and one thrombospondin type 1 domain. All Rspondins regulate Wnt/β-catenin signaling, but have distinct expression patterns. Like other R-Spondins, R-Spondin-1 contains two adjacent cysteinerich furinlike domains (aa 34-135) with one potential N-glycosylation site, followed by a thrombospondin (TSP1) motif (aa 147-207) and a region rich in basic residues (aa 211-263). Only the furinlike domains are needed for β-catenin stabilization. A putative nuclear localization signal at the C-terminus may allow some expression in the nucleus.
References :
(1) Chen, JZ. et al. ,2002, Mol Biol Rep. 2002;29:287.
(2) Kim, K.A. et al., 2006, Cell Cycle. 2006;5:23–26.
(3) Nam, J.S. et al., 2007, Gene Expr. Patterns 7, 306–312.
(4) Kazanskaya, O. et al., 2004, Dev. Cell 7:525.
(5) Kamata, T. et al., 2004, Biochim. Biophys. Acta 1676 (1): 51–62.
(6) Binnerts, M.E. et al., 2007, Proc. Natl. Acad. Sci. U.S.A. 104 (37): 14700–5.
(7) Wei, Q. et al., 2007, J Biol Chem 282:15903–15911.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments